Walleye Trading LLC trimmed its holdings in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI – Get Rating) by 19.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,894 shares of the company's stock after selling 3,823 shares during the quarter. Walleye Trading LLC's holdings in Aerie Pharmaceuticals were worth $119,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in AERI. Nisa Investment Advisors LLC increased its stake in shares of Aerie Pharmaceuticals by 3,142.9% during the first quarter. Nisa Investment Advisors LLC now owns 22,700 shares of the company's stock valued at $207,000 after buying an additional 22,000 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Aerie Pharmaceuticals by 16.0% during the first quarter. Envestnet Asset Management Inc. now owns 43,456 shares of the company's stock valued at $395,000 after buying an additional 5,988 shares during the period. Advisor Group Holdings Inc. increased its stake in shares of Aerie Pharmaceuticals by 33.9% during the first quarter. Advisor Group Holdings Inc. now owns 6,863 shares of the company's stock valued at $62,000 after buying an additional 1,739 shares during the period. Pinnacle Associates Ltd. increased its stake in shares of Aerie Pharmaceuticals by 39.3% during the first quarter. Pinnacle Associates Ltd. now owns 1,031,065 shares of the company's stock valued at $9,383,000 after buying an additional 290,802 shares during the period. Finally, Rice Hall James & Associates LLC increased its stake in shares of Aerie Pharmaceuticals by 39.5% during the first quarter. Rice Hall James & Associates LLC now owns 1,678,609 shares of the company's stock valued at $15,275,000 after buying an additional 475,017 shares during the period. Hedge funds and other institutional investors own 95.94% of the company's stock.
Get
Aerie Pharmaceuticals alerts:
Aerie Pharmaceuticals Stock Performance
Shares of NASDAQ AERI opened at $15.25 on Friday. The company has a market cap of $753.66 million, a PE ratio of -19.80 and a beta of -0.06. The business has a 50-day simple moving average of $15.19 and a two-hundred day simple moving average of $10.98. Aerie Pharmaceuticals, Inc. has a fifty-two week low of $4.81 and a fifty-two week high of $15.37.
Analysts Set New Price Targets
AERI has been the topic of several research reports. StockNews.com lowered Aerie Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, November 15th. Stifel Nicolaus lowered Aerie Pharmaceuticals from a "buy" rating to a "hold" rating and set a $15.00 target price on the stock. in a research note on Tuesday, August 23rd. Needham & Company LLC lowered Aerie Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, August 23rd. Cantor Fitzgerald lowered Aerie Pharmaceuticals from an "overweight" rating to a "neutral" rating and cut their target price for the company from $30.00 to $15.25 in a research note on Tuesday, August 23rd. Finally, HC Wainwright lowered Aerie Pharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 24th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Aerie Pharmaceuticals has an average rating of "Hold" and a consensus target price of $16.90.
Aerie Pharmaceuticals Profile
(Get Rating)
Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.
See Also
- Get a free copy of the StockNews.com research report on Aerie Pharmaceuticals (AERI)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI – Get Rating).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
